PortfoliosLab logo
PortfoliosLab logo
Tools
Performance Analysis
Portfolio Analysis
Factor Model
Portfolios
Lazy PortfoliosUser Portfolios
Discussions
Acasti Pharma Inc (ACST)
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Company Info

ISINCA00430K8730
CUSIP00430K105
SectorHealthcare
IndustryBiotechnology
IPO DateMay 6, 2011

Highlights

Market Cap$34.17M
EPS (TTM)-$1.43
Gross Profit (TTM)-$3.05M
EBITDA (TTM)-$11.39M
Year Range$1.98 - $3.60
Target Price$7.97
Short %1.93%
Short Ratio3.84

Share Price Chart


Loading data...

Compare to other instruments

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Performance

Performance Chart

The chart shows the growth of an initial investment of $10,000 in Acasti Pharma Inc, comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.


-30.00%-20.00%-10.00%0.00%10.00%20.00%JuneJulyAugustSeptemberOctober
14.29%
12.11%
ACST (Acasti Pharma Inc)
Benchmark (^GSPC)

Returns By Period

Acasti Pharma Inc had a return of 16.61% year-to-date (YTD) and 40.42% in the last 12 months. Over the past 10 years, Acasti Pharma Inc had an annualized return of -34.83%, while the S&P 500 had an annualized return of 10.96%, indicating that Acasti Pharma Inc did not perform as well as the benchmark.


PeriodReturnBenchmark
Year-To-Date16.61%20.10%
1 month8.36%-0.39%
6 months13.85%11.72%
1 year40.42%31.44%
5 years (annualized)-49.37%13.30%
10 years (annualized)-34.83%10.96%

Monthly Returns

The table below presents the monthly returns of ACST, with color gradation from worst to best to easily spot seasonal factors. Returns are adjusted for dividends.


JanFebMarAprMayJunJulAugSepOctNovDecTotal
2024-14.19%34.68%2.54%-18.83%-1.83%6.99%-7.53%-2.96%14.50%16.61%
202341.74%-27.90%-10.18%-1.28%18.94%-2.76%-18.11%-20.16%35.12%-15.21%-8.05%33.18%-3.86%
2022-8.73%-2.61%8.93%-13.93%-6.68%-12.45%-3.47%-1.75%-28.28%-3.00%-26.01%19.63%-60.24%
2021100.77%10.34%-16.67%-17.83%1.28%12.46%-18.70%-26.89%-25.09%-16.50%-19.16%-6.67%-51.54%
2020-70.04%-41.68%-11.35%60.74%3.77%-25.89%62.01%-67.80%-18.19%-7.09%55.91%12.07%-86.73%
201928.62%0.93%-5.56%-15.00%3.78%26.69%111.40%-22.41%1.07%-2.65%8.15%23.12%194.51%
201819.86%-11.59%2.10%-24.50%-10.27%-17.51%2.93%-4.89%131.18%-22.48%-27.00%13.96%-11.76%
20171.60%-1.57%8.80%-5.88%0.55%2.56%-0.00%-2.85%10.73%-9.79%30.37%-43.54%-24.58%
2016-38.82%-3.85%1.33%-7.24%6.38%-8.00%12.32%-14.19%34.39%-25.03%4.48%-10.71%-50.98%
2015-8.00%19.57%-12.82%-17.21%-16.52%-4.95%14.32%-1.42%-24.25%-15.95%1.77%10.87%-49.00%
20141.60%-0.00%-9.50%-12.12%-14.85%18.60%-2.06%-5.81%-18.17%-29.87%-23.15%20.48%-60.00%
201320.82%-12.31%-6.58%10.80%7.63%11.42%42.40%-37.97%-5.20%-19.41%-35.08%0.81%-41.91%

Risk-Adjusted Performance

Risk-Adjusted Performance Rank

The current rank of ACST is 61, suggesting that the investment has average results relative to other stocks in terms of risk-adjusted performance. This ranking is determined by the cumulative values of the indicators listed below.


The Risk-Adjusted Performance Rank of ACST is 6161
Combined Rank
The Sharpe Ratio Rank of ACST is 5959Sharpe Ratio Rank
The Sortino Ratio Rank of ACST is 6565Sortino Ratio Rank
The Omega Ratio Rank of ACST is 6161Omega Ratio Rank
The Calmar Ratio Rank of ACST is 5757Calmar Ratio Rank
The Martin Ratio Rank of ACST is 6363Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

Risk-Adjusted Performance Indicators

The charts below present risk-adjusted performance metrics for Acasti Pharma Inc (ACST) and compare them to a chosen benchmark (^GSPC). These indicators evaluate an investment's returns against its associated risks.


ACST
Sharpe ratio
The chart of Sharpe ratio for ACST, currently valued at 0.61, compared to the broader market-4.00-2.000.002.004.000.61
Sortino ratio
The chart of Sortino ratio for ACST, currently valued at 1.60, compared to the broader market-4.00-2.000.002.004.001.60
Omega ratio
The chart of Omega ratio for ACST, currently valued at 1.19, compared to the broader market0.501.001.502.001.19
Calmar ratio
The chart of Calmar ratio for ACST, currently valued at 0.42, compared to the broader market0.002.004.006.000.42
Martin ratio
The chart of Martin ratio for ACST, currently valued at 2.63, compared to the broader market0.0010.0020.0030.002.63
^GSPC
Sharpe ratio
The chart of Sharpe ratio for ^GSPC, currently valued at 2.88, compared to the broader market-4.00-2.000.002.004.002.88
Sortino ratio
The chart of Sortino ratio for ^GSPC, currently valued at 3.82, compared to the broader market-4.00-2.000.002.004.003.82
Omega ratio
The chart of Omega ratio for ^GSPC, currently valued at 1.54, compared to the broader market0.501.001.502.001.54
Calmar ratio
The chart of Calmar ratio for ^GSPC, currently valued at 3.52, compared to the broader market0.002.004.006.003.52
Martin ratio
The chart of Martin ratio for ^GSPC, currently valued at 18.62, compared to the broader market0.0010.0020.0030.0018.62

Sharpe Ratio

The current Acasti Pharma Inc Sharpe ratio is 0.61. This value is calculated based on the past 1 year of trading data and takes into account price changes and dividends.

Use the chart below to compare the Sharpe ratio of Acasti Pharma Inc with the selected benchmark, providing insights into the investment's historical performance in terms of risk-adjusted returns. Go to the Sharpe ratio tool for more fine-grained control over the calculation options.


Rolling 12-month Sharpe Ratio0.001.002.003.00JuneJulyAugustSeptemberOctober
0.61
3.17
ACST (Acasti Pharma Inc)
Benchmark (^GSPC)

Dividends

Dividend History


Acasti Pharma Inc doesn't pay dividends

Drawdowns

Drawdowns Chart

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.


-100.00%-80.00%-60.00%-40.00%-20.00%0.00%JuneJulyAugustSeptemberOctober
-99.83%
-0.96%
ACST (Acasti Pharma Inc)
Benchmark (^GSPC)

Worst Drawdowns

The table below displays the maximum drawdowns of the Acasti Pharma Inc. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Acasti Pharma Inc was 99.91%, occurring on Sep 22, 2023. The portfolio has not yet recovered.

The current Acasti Pharma Inc drawdown is 99.83%.


Depth

Start

To Bottom

Bottom

To Recover

End

Total

-99.91%Aug 6, 20132541Sep 22, 2023
-26.08%Jun 8, 201128Jan 24, 20121Feb 14, 201229
-22.89%Dec 7, 201261Mar 21, 201355Jun 11, 2013116
-18.29%May 18, 201237Nov 8, 20126Nov 30, 201243
-4.47%Aug 1, 20131Aug 1, 20132Aug 5, 20133

Volatility

Volatility Chart

The current Acasti Pharma Inc volatility is 17.54%, representing the average percentage change in the investments's value, either up or down over the past month. The chart below shows the rolling one-month volatility.


0.00%5.00%10.00%15.00%20.00%25.00%JuneJulyAugustSeptemberOctober
17.54%
2.73%
ACST (Acasti Pharma Inc)
Benchmark (^GSPC)

Financials

Financial Performance

The chart below illustrates the trends in the financial health of Acasti Pharma Inc over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

Annual
Quarterly

0.0

Historical P/E Ratio Chart

The chart below displays the historical trend of the price-to-earnings (P/E) ratio for Acasti Pharma Inc.


Loading data...

Income Statement


Income Statement
Balance Sheet
Cash Flow
Annual
Quarterly

TTM
Revenue

Total Revenue

Cost Of Revenue

Gross Profit

Operating Expenses

Selling, General & Admin Expenses

R&D Expenses

Depreciation And Amortization

Total Operating Expenses

Income

Income Before Tax

Operating Income

EBITDA

EBIT

Earnings From Continuing Operations

Net Income

Income Tax Expense

Other Non-Operating Income (Expenses)

Extraordinary Items

Discontinued Operations

Effect Of Accounting Charges

Non Recurring

Minority Interest

Other Items

Interest Income

Interest Expense

Net Interest Income

Values in undefined except per share items